Jump to content

User:Fmidan/Draft: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Fmidan (talk | contribs)
64 edits
No edit summary
Fmidan (talk | contribs)
64 edits
No edit summary
Line 62: Line 62:
The company released its first commercial [[assay]], or test, called FoundationOne in 2012.<ref>{{cite news |title=Roche Holding to Pay $1.03 Billion for Diagnostics-Firm Stake |author=Ron Winslow |url=https://www.wsj.com/articles/roche-holding-to-pay-1-03-billion-for-diagnostics-firm-stake-1421042401 |work=[[The Wall Street Journal]] |date=January 12, 2015 |accessdate=18 January 2018 |quote=Foundation says it has sold about 35,000 tests since the first one was launched in June 2012.}}</ref> Unlike first-generation genomic profiles of tumors, FoundationOne had the ability to test for genetic mutations in approximately 280 genes at once.<ref>{{cite news |title=Bill Gates helps genomic tests startup lay firm foundation |author=Emily Mullin |url=https://www.fiercebiotech.com/medical-devices/bill-gates-helps-genomic-tests-startup-lay-firm-foundation |work=FierceBiotech |date=January 22, 2013 |accessdate=18 January 2018 |quote=Already considered a novelty in cancer medicine, Foundation's $5,800 complex molecular test provides a more comprehensive look at a patient's cancer--allowing doctors to test a tumor sample for genetic mutations in 280 genes that could be driving tumor growth. This is different from current first-generation genetics tests for cancer, which are designed to find one or a few genomic alterations.}}</ref> Results from the test’s validation were published in ‘’[[Nature Biotechnology]]’’ in 2013.<ref name="FramptonFichtenholtz2013">{{cite journal|last1=Frampton|first1=Garrett M|last2=Fichtenholtz|first2=Alex|last3=Otto|first3=Geoff A, et al.||title=Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing|journal=Nature Biotechnology|volume=31|issue=11|year=2013|page=1023|issn=1087-0156|doi=10.1038/nbt.2696}}</ref>
The company released its first commercial [[assay]], or test, called FoundationOne in 2012.<ref>{{cite news |title=Roche Holding to Pay $1.03 Billion for Diagnostics-Firm Stake |author=Ron Winslow |url=https://www.wsj.com/articles/roche-holding-to-pay-1-03-billion-for-diagnostics-firm-stake-1421042401 |work=[[The Wall Street Journal]] |date=January 12, 2015 |accessdate=18 January 2018 |quote=Foundation says it has sold about 35,000 tests since the first one was launched in June 2012.}}</ref> Unlike first-generation genomic profiles of tumors, FoundationOne had the ability to test for genetic mutations in approximately 280 genes at once.<ref>{{cite news |title=Bill Gates helps genomic tests startup lay firm foundation |author=Emily Mullin |url=https://www.fiercebiotech.com/medical-devices/bill-gates-helps-genomic-tests-startup-lay-firm-foundation |work=FierceBiotech |date=January 22, 2013 |accessdate=18 January 2018 |quote=Already considered a novelty in cancer medicine, Foundation's $5,800 complex molecular test provides a more comprehensive look at a patient's cancer--allowing doctors to test a tumor sample for genetic mutations in 280 genes that could be driving tumor growth. This is different from current first-generation genetics tests for cancer, which are designed to find one or a few genomic alterations.}}</ref> Results from the test’s validation were published in ‘’[[Nature Biotechnology]]’’ in 2013.<ref name="FramptonFichtenholtz2013">{{cite journal|last1=Frampton|first1=Garrett M|last2=Fichtenholtz|first2=Alex|last3=Otto|first3=Geoff A, et al.||title=Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing|journal=Nature Biotechnology|volume=31|issue=11|year=2013|page=1023|issn=1087-0156|doi=10.1038/nbt.2696}}</ref>


The company also began partnering with [[Pharmaceutical industry|pharmaceutical companies]] to analyze patient samples.<ref name=Burke/> The first such program was piloted with [[Novartis]] in 2011,<ref name=Karow/> and by 2018, the company had more than 30 partnerships.<ref name=Karrow5>{{cite news |title=Foundation Medicine to Grow Clinical Testing, Pharma Business in 2018 |author=Julia Karrow |url=https://www.genomeweb.com/molecular-diagnostics/foundation-medicine-grow-clinical-testing-pharma-business-2018#.W1M9QNhKhn6 |work=GenomeWeb|date=8 March 2018|accessdate=18 June 2018}}</ref>
The company also began partnering with [[Pharmaceutical industry|pharmaceutical companies]] to analyze patient samples.<ref>{{cite news |title=Foundation Medicine: Personalizing Cancer Drugs |author= Adrienne Burke |url=https://www.technologyreview.com/s/426987/foundation-medicine-personalizing-cancer-drugs/ |work=[[MIT Technology Review]] |date=February 21, 2012 |accessdate=18 January 2018 |quote= So far, most of Foundation’s business is coming from five drug companies seeking genetic explanations for why their cancer drugs work spectacularly in some patients but not at all in others.}}</ref> The first such program was piloted with [[Novartis]] in 2011,<ref name=Karow>{{cite news |title=Foundation Medicine Developing Targeted Sequencing Test for 'Clinically Actionable' Cancer Genes |author=Julia Karow |url=https://www.genomeweb.com/sequencing/foundation-medicine-developing-targeted-sequencing-test-clinically-actionable-ca |work=Genome Web |date=April 13, 2011 |accessdate=18 January 2018 |quote=The company is currently using the test in a pilot collaboration with Novartis and plans other partnerships with pharmaceutical firms and academic medical centers to demonstrate its analytical validity and clinical utility.}}</ref> and by 2018, the company had more than 30 partnerships.<ref name=Karrow5>{{cite news |title=Foundation Medicine to Grow Clinical Testing, Pharma Business in 2018 |author=Julia Karrow |url=https://www.genomeweb.com/molecular-diagnostics/foundation-medicine-grow-clinical-testing-pharma-business-2018#.W1M9QNhKhn6 |work=GenomeWeb|date=8 March 2018|accessdate=18 June 2018 |quote=Cox said the company already has more than 30 biopharma partnership contracts today, a number it plans to grow, both with new and existing partners.}}</ref>


Foundation Medicine launched its second test, a [[Hematology|hematological]] [[biomarker]] assay called FoundationOneHeme, in 2013.<ref name=Karow3/> The company collaborated with [[Memorial Sloan-Kettering Cancer Center]] researchers on the test, who validated the assay on approximately 400 patient samples<ref name=Karow3/> and published the findings in ‘’[[Blood (journal)|Blood]]’’ in 2016.<ref name="HeAbdel-Wahab2016">{{cite journal|last1=He|first1=J.|last2=Abdel-Wahab|first2=O.|last3=Nahas|first3=M. K., et al.|title=Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting|journal=Blood|volume=127|issue=24|year=2016|page=3009|issn=0006-4971|doi=10.1182/blood-2015-08-664649}}</ref>
Foundation Medicine launched its second test, a [[Hematology|hematological]] [[biomarker]] assay called FoundationOneHeme, in 2013.<ref name=Karow3/> The company collaborated with [[Memorial Sloan-Kettering Cancer Center]] researchers on the test, who validated the assay on approximately 400 patient samples<ref name=Karow3/> and published the findings in ‘’[[Blood (journal)|Blood]]’’ in 2016.<ref name="HeAbdel-Wahab2016">{{cite journal|last1=He|first1=J.|last2=Abdel-Wahab|first2=O.|last3=Nahas|first3=M. K., et al.|title=Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting|journal=Blood|volume=127|issue=24|year=2016|page=3009|issn=0006-4971|doi=10.1182/blood-2015-08-664649}}</ref>

Revision as of 00:40, 14 September 2018

Foundation Medicine, Inc.
Headquarters
Cambridge, Massachusetts
,
United States
Key people
  • Troy Cox (CEO)[1]
  • Jason Ryan (CFO)[1]
  • Tom Civik (CCO)[1]
  • Melanie Nallicheri (CBO)[2]
ProductsFoundationOne FoundationOneHeme FoundationACT FoundationOne CDx Foundation Insights FoundationSmartTrials
OwnersRoche
Number of employees
501-1,000 (July 2018)[3]
WebsiteOfficial website

Foundation Medicine, Inc. is a public American company based in Cambridge, Massachusetts which develops, manufactures, and sells genomic profiling assays for solid tumors, hematologic malignancies, and sarcomas.[4] The company's tests are based on next-generation sequencing technology.[5] The company also provides data and related services to pharmaceutical companies and researchers.[6]

In addition to its Cambridge headquarters, the company has laboratory facilities in Penzberg, Germany[7] and Morrisville, North Carolina.[8]

Products and offerings

Foundation Medicine’s products support personalized medicine and precision medicine and include genomic tests used to test solid tumors and blood-based cancers and sarcomas,[9] as well as data services that are designed to help pharmaceutical companies develop and test new personalized medicines.[10]

The company’s assays are used by clinicians[11] and pharmaceutical companies[12] to analyze cancer biomarkers in patient tumor samples.[13]

Test results include an analysis of genomic alterations relevant to available cancer therapies,[14] other genomic markers that may inform response to cancer immunotherapy,[15][16] and potential targeted therapies,[17] and/or clinical trial eligibility.[18]

In the clinical setting, the tests are designed to help doctors match patients to these various treatment pathways.[19][20]

Foundation Medicine’s technology and data offerings are intended to support biopharma clinical research and aimed at improving patient outcomes by aiding drug development and clinical trial design through molecular data insights.[21][22]

Clinical Products

  • FoundationOne is a comprehensive genomic profiling (CGP) test that is used in solid tumors.[23]
  • FoundationOneHeme is a CGP assay for hematologic cancers and sarcomas that employs both DNA and RNA sequencing.[24] The test sequences more than 400 cancer-related genes and, using RNA-seq, can assess gene fusions in 265 genes that are common mutations among sarcomas and hematologic malignancies.[25]
  • FoundationACT is a blood-based circulating tumor DNA (ctDNA) assay for use with solid tumors that can detect cancer-driving alterations in more than 60 genes.[26][27]
  • FoundationOne CDx is a CGP test that can be used with all solid tumors and includes several companion diagnostics providing information for five tumor types: ovarian, lung, breast, colorectal, and melanoma.[28]

Technology and data services

  • The company’s FoundationCore database[29] contains more than 200,000 genomic profiles sourced from the results of the company’s assays.[30] The database also includes information on 150 subtypes of cancer.[31] The data are used by the company to provide treatment information to clinicians and in partnerships with healthcare technology and pharmaceutical companies for use in research and clinical development.[32]

History

Foundation Medicine was founded in Cambridge, Massachusetts.[33] The company was conceived after Broad Institute researchers Levi Garraway, M.D., Ph.D. and Matthew Meyerson, M.D., Ph.D. published a 2007 paper detailing an efficient method for large-panel testing of 238 DNA mutations.[34] Founding academic advisors from the Broad Institute, Dana–Farber Cancer Institute, Harvard Medical School, and MIT, including Garraway, Meyerson, Eric Lander, Ph.D. and Todd Golub, M.D, laid the groundwork for the company over two years.[35][36]

Foundation Medicine launched in 2010 with a $25 million Series A financing led by Third Rock Ventures.[37] Other early investors included Google Ventures, Kleiner Perkins Caufield & Byers, and Bill Gates.[38] Alexis Borisy served as the founding chief executive officer of the company.[39] He was succeeded by Michael Pellini in 2011.[40]

The company released its first commercial assay, or test, called FoundationOne in 2012.[41] Unlike first-generation genomic profiles of tumors, FoundationOne had the ability to test for genetic mutations in approximately 280 genes at once.[42] Results from the test’s validation were published in ‘’Nature Biotechnology’’ in 2013.[43]

The company also began partnering with pharmaceutical companies to analyze patient samples.[44] The first such program was piloted with Novartis in 2011,[45] and by 2018, the company had more than 30 partnerships.[46]

Foundation Medicine launched its second test, a hematological biomarker assay called FoundationOneHeme, in 2013.[47] The company collaborated with Memorial Sloan-Kettering Cancer Center researchers on the test, who validated the assay on approximately 400 patient samples[47] and published the findings in ‘’Blood’’ in 2016.[48]

The company held its initial public offering in August 2013.[49] The following year, Priority Health in Michigan became the first healthcare plan in the United States to cover the company’s tests.[50]

In 2015, Foundation Medicine reached a US$1.2 billion deal with Swiss holding company Roche that gave Roche a majority stake in the company.[51][52] In June, 2018, Roche announced it would acquire the outstanding shares of Foundation Medicine for $2.4 billion ($137 per share).[53]

The company established the Precision Medicine Exchange Consortium (PMEC) in 2015, a data-sharing program designed to allow organizations to share de-identified and HIPAA compliant genomic information and treatment data for advanced research in the area of precision oncology.[54] At launch, seven institutions were members of the exchange.[54]

In 2016, Foundation Medicine released anonymized records detailing genomic data on cancers from 18,000 adult patients. These records were drawn from its FoundationCore resource, and provided to the National Cancer Institute’s (NCI) Genomic Data Commons (GDC) portal in an effort to facilitate and accelerate research in precision medicine under the National Cancer Moonshot and Precision Medicine Initiative created by the Obama administration.[55] The contribution was the largest such donation to the NCI[56] and more than doubled the number of records available to the GDC.[57]

The company introduced two products in 2016—FoundationACT, a liquid biopsy assay for use with solid tumors, and FoundationFocus CDx BRCA, a companion diagnostic test for Rubraca (rucaparib) in ovarian cancer that was approved by the Food and Drug Administration (FDA) in December of that year.[58]

In January 2017, Foundation Medicine’s Board of Directors appointed Troy Cox as chief executive officer to succeed Michael Pellini, who became chairman of the board.[51]

In December 2017, the company’s assay FoundationOne CDx received approval from the FDA and a initial National Coverage Determination (NCD) from the Centers for Medicare & Medicaid Services (CMS).[59] FoundationOne CDx was the second product to be approved under the parallel review program run by the FDA and CMS.[60]

In March 2018, CMS issued a coverage policy regarding next-generation sequencing (NGS) testing, including a final National Coverage Determination for FoundationOne CDx, enabling coverage for eligible Medicare and Medicare Advantage patients who receive the test.[61]

TMB and bTMB research

FoundationOne assesses a large number of genes and sequences approximately 1.1 megabases (Mb) of the coding genome, allowing it to accurately assess TMB, which the company has used both in reporting and other research applications.[58][62]

In 2017, a summary of Foundation Medicine’s TMB results in over 88,150 clinical samples was presented at the American Association for Cancer Research (AACR). The update noted high TMB in several cancers, including advanced skin, lung, and bladder cancer.[63] The company also presented evidence at the 2017 European Society for Medical Oncology (ESMO) meeting that immunotherapy response can be predicted using an assay the company developed measuring tumor mutational burden from a blood, rather than tissue, sample (bTMB), rather than tissue, in certain indications. As of 2018, the test is being used in a Roche clinical trial (Blood First Assay Screening Trial) for immunotherapy Tecentriq.[64]

See also

References

  1. ^ a b c "Foundation Medicine's (FMI) CEO Troy Cox on Q1 2018 Results - Earnings Call Transcript". SeekingAlpha. Retrieved 1 July 2018.
  2. ^ Jonathan Saltzman (30 November 2017). "Cambridge firm has high hopes for diagnostic test for cancer". The Boston Globe. Retrieved 18 June 2018.
  3. ^ "Company Overview of Foundation Medicine, Inc". Bloomberg News. Retrieved 1 July 2018.
  4. ^ Staff (15 January 2015). "Cambridge startup soars on Roche stake". Business. The Boston Globe.
  5. ^ Staff (9 January 2015). "Foundation Medicine on the Added Value of NGS Cancer Tests". Clinical Informatics News. Needham, Massachusetts, United States: Cambridge Healthtech Institute.
  6. ^ "Company Overview of Foundation Medicine, Inc". Bloomberg News. Retrieved 1 July 2018. Foundation Medicine, Inc. provides various molecular information products in the United States. The company's molecular information platform includes proprietary methods and algorithms to analyze specimens across various types of cancer, as well as for incorporating that information into clinical care; and offers genomic insights about each patient's individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted therapies and immunotherapies.
  7. ^ Julia Karow (August 3, 2016). "Foundation Medicine Pursuing Multiple Strategies to Expand Reimbursement for Clinical Tests". Genome Web. Retrieved 18 January 2018. The company is also making efforts to sell reimbursable tests abroad. According to Kafka, it has laboratory operations in Penzberg in Southern Germany, where its partner Roche Diagnostics maintains a large facility with 5,600 employees. That new laboratory supports all of Foundation's clinical tests and serves as a regional hub for test commercialization in Europe.
  8. ^ Allan Maurer (September 28, 2017). "Foundation Medicine building RTP lab into key hub". WRAL TechWire. Retrieved 18 January 2018. Foundation Medicine, a Cambridge, Massachusetts firm selling genomic cancer tests, opened a precision health laboratory in Morrisville last year that it is growing into a major facility.
  9. ^ Dr. Hung Tran (23 April 2018). "Foundation Medicine: To Profit From The Increasing Trend Of Personalized Treatment". Seeking Alpha. Retrieved 13 September 2018. As alluded to, the aforesaid genomic test can detect the DNA changes driving cancer growth to help physicians deliver the more effective personalized treatment. In specific, the next-generation sequencing ("NGS") can detect all four classes of base pairs mutations - substitution, insertion/deletion, duplication, and rearrangement - in solid tumors, sarcomas, and blood malignancies
  10. ^ "Company Overview of Foundation Medicine, Inc". Bloomberg News. Retrieved 1 July 2018. The company's molecular information platform includes proprietary methods and algorithms to analyze specimens across various types of cancer, as well as for incorporating that information into clinical care; and offers genomic insights about each patient's individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted therapies and immunotherapies.
  11. ^ Susan Young Rojahn (12 November 2013). "Genomics Could Blow Up the Clinical Trial". MIT Technology Review. Retrieved 18 June 2018. Foundation Medicine offers a diagnostic tumor screen for use by doctors treating cancer patients. Doctors send in a biopsied sample of a patient's tumor, and Foundation Medicine sequences the tumor's DNA and then reports back any DNA mutations that suggest a certain drug will or won't work
  12. ^ Adrienne Burke (February 21, 2012). "Foundation Medicine: Personalizing Cancer Drugs". MIT Technology Review. Retrieved 18 January 2018. So far, most of Foundation's business is coming from five drug companies seeking genetic explanations for why their cancer drugs work spectacularly in some patients but not at all in others.
  13. ^ Dr. Hung Tran (23 April 2018). "Foundation Medicine: To Profit From The Increasing Trend Of Personalized Treatment". Seeking Alpha. Retrieved 13 September 2018. It provides biomarker information and mutational analysis to match patients to the best approved therapeutics, immunotherapies, and clinical trials.
  14. ^ Adrienne Burke (February 21, 2012). "Foundation Medicine: Personalizing Cancer Drugs". MIT Technology Review. Retrieved 18 January 2018. Foundation will extract the DNA, sequence scores of cancer genes, and prepare a report to steer doctors and patients toward drugs, most still in early testing, that are known to target the cellular defects caused by the DNA errors the analysis turns up. Pellini says that about 70 percent of cases studied to date have yielded information that a doctor could act on—whether by prescribing a particular drug, stopping treatment with another, or enrolling the patient in a clinical trial.
  15. ^ Ken Garber (27 June 2018). "Mutation-counting blood test could predict if cutting-edge immunotherapies can beat a cancer". Science Magazine. Retrieved 18 July 2018. Certain random mutations that accumulate in rapidly dividing tumor cells can spur the immune system to attack the cancer. Researchers are now learning that the extent of such mutations can predict whether a cancer will respond to new, powerful, immune-based therapies. A recently unveiled blood test for this so-called tumor mutational burden (TMB) could help make it a practical tool for guiding cancer treatment. The blood TMB test, also from Foundation Medicine, may prove just as effective as the tissue test.
  16. ^ Susan Young Rojahn (12 November 2013). "Genomics Could Blow Up the Clinical Trial". MIT Technology Review. Retrieved 18 June 2018. Doctors send in a biopsied sample of a patient's tumor, and Foundation Medicine sequences the tumor's DNA and then reports back any DNA mutations that suggest a certain drug will or won't work
  17. ^ Emily Mullin (January 22, 2013). "Bill Gates helps genomic tests startup lay firm foundation". FierceBiotech. Retrieved 18 January 2018. Physicians ordering the test receive an interpretive report that matches DNA mutations in tumors with targeted therapies, which could have a profound impact on how cancer patients are treated.
  18. ^ Ron Winslow (January 12, 2015). "Roche Holding to Pay $1.03 Billion for Diagnostics-Firm Stake". The Wall Street Journal. Retrieved 18 January 2018. Doctors can use the results to try to match patients with available drugs that target the identified mutations or with clinical trials testing such drugs.
  19. ^ Ariela Katz. "Biotech Executive Offers Glimpse of Testing Future". OncLive. Retrieved 18 January 2018. allows a doctor treating patients with cancer to see if their patient is eligible for an FDA-approved therapy or to evaluate, from a molecular standpoint, whether they're eligible to participate in specific clinical trials
  20. ^ Susan Young Rojahn (12 November 2013). "Genomics Could Blow Up the Clinical Trial". MIT Technology Review. Retrieved 18 June 2018. Foundation Medicine offers a diagnostic tumor screen for use by doctors treating cancer patients. Doctors send in a biopsied sample of a patient's tumor, and Foundation Medicine sequences the tumor's DNA and then reports back any DNA mutations that suggest a certain drug will or won't work
  21. ^ Stephanie Baum (2 December 2014). "Big data meets genomic profiling to improve clinical trials for cancer drugs". MedCityNews. Retrieved 18 June 2018. The jointly developed information products born from this collaboration will provide life science companies with a powerful new tool to access actionable data that informs the development of targeted new cancer therapies
  22. ^ Abigail Ballou (December 27, 2016). "Improving Patient Outcomes Through Data Exchange". MedTech Boston. Retrieved 18 January 2018. Cambridge-based Foundation Medicine, a molecular information company that sells genomic profiling tests for solid tumors and hematologic malignancies, is leading a new data exchange partner program, the Precision Medicine Exchange Consortium (PMEC) to facilitate the exchange of molecular information and research and improve cancer care. Ultimately, the hope is that PMEC will encourage collaboration and contribute to an ecosystem that will make it easier to identify patient populations who qualify for clinical trials, help with drug discovery and drug development programs, and improve patient outcomes.
  23. ^ Don Seiffert (December 4, 2014). "Foundation Medicine still growing a year after launching blood-cancer test". Boston Business Journal. Retrieved 18 January 2018. Foundation's comprehensive genomic profiling tests are FoundationOne for solid tumor cancers and FoundationOne Heme, aimed at blood cancers
  24. ^ Julia Karow (December 11, 2013). "LabCorp Steps into NGS-based Oncology Market as Foundation Medicine Adds Hematologic Cancer Test". Genome Web. Retrieved 18 January 2018. FoundationOne Heme, for hematologic cancers and certain sarcomas and pediatric cancers. FoundationOne Heme combines targeted DNA sequencing with RNA-seq.
  25. ^ Julia Karow (December 11, 2013). "LabCorp Steps into NGS-based Oncology Market as Foundation Medicine Adds Hematologic Cancer Test". Genome Web. Retrieved 18 January 2018. It sequences 405 cancer-related genes and covers all classes of genomic alterations, including single-base substitutions, insertions and deletions, copy number alterations, and select gene rearrangements. In addition, the test applies RNA-seq to 265 genes in order to assess gene fusions in those genes, which are common driver mutations in hematologic cancers, sarcomas, and pediatric cancers.
  26. ^ Emmie Martin (June 13, 2016). "Meet the top 100 business visionaries creating value for the world". Business Insider. Retrieved 13 September 2018. the company also launched its liquid biopsy test, called FoundationACT, which looks for circulating tumor DNA in the blood as another way to monitor cancer treatment.
  27. ^ Jason Harris (September 5, 2018). "Rafametinib/Sorafenib Combo May Improve Survival in RAS-Mutated HCC". Targeted Oncology. Retrieved 13 September 2018. FoundationACT, a next-generation sequencing (NGS)-based circulating tumor DNA (ctDNA) hybrid-capture-based assay. FoundationACT examines 62 genes for all classes of alterations including base substitutions, insertions and deletions, copy-number variations, and rearrangements/fusions.
  28. ^ Jonathan Saltzman (June 20, 2018). "Roche will pay $2.4 billion to complete its takeover of Foundation Medicine". The Boston Globe. Retrieved 13 September 2018. In November, federal regulators approved a diagnostic test by Foundation called FoundationOne CDx that can detect all four classes of alterations in 324 cancer-related genes that cause solid tumors. That includes tumors found in the lung, colon, breasts, ovaries, and — in cases of melanoma — skin.
  29. ^ Alex Philippidis (January 16, 2018). "Pfizer Joins Foundation Medicine to Develop Cancer CDx". GEN. Retrieved 18 January 2018. FoundationCore knowledge base, which according to the company includes more than 120,000 genomic profiles and data on more than 150 cancer subtypes.
  30. ^ Shanthi Rexaline (February 15, 2018). "Foundation Medicine Set For 'Material Upside,' Cowen Says In Bullish Initiation". Yahoo! News. Retrieved 29 June 2018. Foundation generated more than 200,000 comprehensive genetic profiles in cancer since 2012
  31. ^ Alex Philippidis (January 16, 2018). "Pfizer Joins Foundation Medicine to Develop Cancer CDx". GEN. Retrieved 18 January 2018. FoundationCore knowledge base, which according to the company includes more than 120,000 genomic profiles and data on more than 150 cancer subtypes.
  32. ^ "Company Overview of Foundation Medicine, Inc". Bloomberg News. Retrieved 1 July 2018. The company's molecular information platform includes proprietary methods and algorithms to analyze specimens across various types of cancer, as well as for incorporating that information into clinical care; and offers genomic insights about each patient's individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted therapies and immunotherapies.
  33. ^ Allan Maurer (September 28, 2017). "Foundation Medicine building RTP lab into key hub". WRAL TechWire. Retrieved 18 January 2018. Foundation, founded in Cambridge, Mass., in 2010
  34. ^ Adrienne Burke (February 21, 2012). "Foundation Medicine: Personalizing Cancer Drugs". MIT Technology Review. Retrieved 18 January 2018. The science underlying Foundation Medicine had its roots in a 2007 paper published by Levi Garraway and Matthew Meyerson, cancer researchers at the Broad Institute, in Cambridge, Massachusetts. They came up with a speedy way to find 238 DNA mutations then known to make cells cancerous.
  35. ^ Adrienne Burke (February 21, 2012). "Foundation Medicine: Personalizing Cancer Drugs". MIT Technology Review. Retrieved 18 January 2018. He and Meyerson began talking with Broad director Eric Lander about how to get that information into the hands of oncologists. What followed was nearly two years of strategizing between Broad scientists and a parade of patent lawyers, oncologists, and insurance experts, which Garraway describes as being "like a customized business-school curriculum around how we're going to do diagnostics in the new era."
  36. ^ Julia Karow (April 13, 2011). "Foundation Medicine Developing Targeted Sequencing Test for 'Clinically Actionable' Cancer Genes". Genome Web. Retrieved 18 January 2018. The company boasts a roaster of well-known founding academic advisors from the Broad Institute, Dana Farber Cancer Institute, Harvard Medical School, and MIT: Eric Lander, Todd Golub, Levi Garraway, and Matthew Meyerson.
  37. ^ Julia Karow (April 13, 2011). "Foundation Medicine Developing Targeted Sequencing Test for 'Clinically Actionable' Cancer Genes". Genome Web. Retrieved 18 January 2018. Last April, the Cambridge, Mass.-based company completed a $25 million Series A funding round that was led by Third Rock Ventures, where Borisy is also a partner.
  38. ^ Emily Mullin (January 22, 2013). "Bill Gates helps genomic tests startup lay firm foundation". FierceBiotech. Retrieved 18 January 2018. Foundation was by no means hurting for investors--the Cambridge, MA, biotech had already garnered support from the likes of Google Ventures and Kleiner Perkins Caufield & Byers. But Gates' investment has given the company an even bigger boost.
  39. ^ Julia Karow (April 13, 2011). "Foundation Medicine Developing Targeted Sequencing Test for 'Clinically Actionable' Cancer Genes". Genome Web. Retrieved 18 January 2018. Alexis Borisy, a partner with Third Rock who is chairman of Foundation.
  40. ^ Max Stendahl (January 6, 2017). "Cambridge's Foundation Medicine gets new CEO in leadership shuffle". Boston Business Journal. Retrieved 18 January 2018. The company said that its current CEO, Michael Pellini, who has served in that role since 2011, would become chairman of its board of directors on that date.
  41. ^ Ron Winslow (January 12, 2015). "Roche Holding to Pay $1.03 Billion for Diagnostics-Firm Stake". The Wall Street Journal. Retrieved 18 January 2018. Foundation says it has sold about 35,000 tests since the first one was launched in June 2012.
  42. ^ Emily Mullin (January 22, 2013). "Bill Gates helps genomic tests startup lay firm foundation". FierceBiotech. Retrieved 18 January 2018. Already considered a novelty in cancer medicine, Foundation's $5,800 complex molecular test provides a more comprehensive look at a patient's cancer--allowing doctors to test a tumor sample for genetic mutations in 280 genes that could be driving tumor growth. This is different from current first-generation genetics tests for cancer, which are designed to find one or a few genomic alterations.
  43. ^ Frampton, Garrett M; Fichtenholtz, Alex; Otto, Geoff A; et al. (2013). "Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing". Nature Biotechnology. 31 (11): 1023. doi:10.1038/nbt.2696. ISSN 1087-0156. {{cite journal}}: Cite has empty unknown parameter: |1= (help); Explicit use of et al. in: |first3= (help)
  44. ^ Adrienne Burke (February 21, 2012). "Foundation Medicine: Personalizing Cancer Drugs". MIT Technology Review. Retrieved 18 January 2018. So far, most of Foundation's business is coming from five drug companies seeking genetic explanations for why their cancer drugs work spectacularly in some patients but not at all in others.
  45. ^ Julia Karow (April 13, 2011). "Foundation Medicine Developing Targeted Sequencing Test for 'Clinically Actionable' Cancer Genes". Genome Web. Retrieved 18 January 2018. The company is currently using the test in a pilot collaboration with Novartis and plans other partnerships with pharmaceutical firms and academic medical centers to demonstrate its analytical validity and clinical utility.
  46. ^ Julia Karrow (8 March 2018). "Foundation Medicine to Grow Clinical Testing, Pharma Business in 2018". GenomeWeb. Retrieved 18 June 2018. Cox said the company already has more than 30 biopharma partnership contracts today, a number it plans to grow, both with new and existing partners.
  47. ^ a b Cite error: The named reference Karow3 was invoked but never defined (see the help page).
  48. ^ He, J.; Abdel-Wahab, O.; Nahas, M. K.; et al. (2016). "Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting". Blood. 127 (24): 3009. doi:10.1182/blood-2015-08-664649. ISSN 0006-4971. {{cite journal}}: Explicit use of et al. in: |first3= (help)
  49. ^ Don Seiffert (December 4, 2014). "Foundation Medicine still growing a year after launching blood-cancer test". Boston Business Journal. Retrieved 18 January 2018.
  50. ^ Don Seiffert (November 20, 2014). "Foundation Medicine's shares gain on flurry of good news ahead of earnings call". Boston Business Journal. Retrieved 18 January 2018.
  51. ^ a b Max Stendahl (January 6, 2017). "Cambridge's Foundation Medicine gets new CEO in leadership shuffle". Boston Business Journal. Retrieved 18 January 2018.
  52. ^ Ron Winslow (January 12, 2015). "Roche Holding to Pay $1.03 Billion for Diagnostics-Firm Stake". The Wall Street Journal. Retrieved 18 January 2018.
  53. ^ Shields, Michael; Hirschler, Ben (19 June 2018). "Roche pays $2.4 billion for rest of cancer expert Foundation Medicine". Reuters. {{cite journal}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)
  54. ^ a b Cite error: The named reference Ballou was invoked but never defined (see the help page).
  55. ^ Constance Gustke (July 6, 2017). "Joe Biden's moonshot to crack the code on cancer, one of the biggest killers in America". CNBC. Retrieved 18 January 2018.
  56. ^ "Industry Playbook". AACC. September 1, 2016. Retrieved 18 January 2018.
  57. ^ Don Seiffert (June 29, 2016). "Cambridge diagnostic firm to double size of 'Moonshot' cancer database". Boston Business Journal. Retrieved 18 January 2018.
  58. ^ a b Cite error: The named reference Katz was invoked but never defined (see the help page).
  59. ^ "JPM Healthcare Day 1: Genomic Health, Foundation Medicine, Qiagen, Myriad, and Guardant". 360Dx. January 9, 2018. Retrieved 18 January 2018.
  60. ^ Alex Philippidis (January 16, 2018). "Pfizer Joins Foundation Medicine to Develop Cancer CDx". GEN. Retrieved 18 January 2018.
  61. ^ Alex Philippidis (22 May 2018). "Breaking NGS Ground". GEN. Retrieved 18 June 2018.
  62. ^ Chalmers, Zachary R.; Connelly, Caitlin F.; Fabrizio, David; et al. (2017). "Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden". Genome Medicine. 9 (1). doi:10.1186/s13073-017-0424-2. ISSN 1756-994X. {{cite journal}}: Explicit use of et al. in: |first3= (help)CS1 maint: unflagged free DOI (link)
  63. ^ Cite error: The named reference Garber was invoked but never defined (see the help page).
  64. ^ Molika Ashford (September 12, 2017). "Foundation Medicine Positions Blood-Based TMB Test as Companion Dx to First-Line Immunotherapy". Genome Web. Retrieved 18 January 2018.

Official website

Category:Biotechnology companies of the United States Category:Companies based in Cambridge, Massachusetts Category:Companies listed on NASDAQ Category:Genomics companies Category:Health care companies based in Massachusetts

Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Fmidan/Draft&oldid=859428746"